Latest Insider Transactions at Denali Therapeutics Inc. (DNLI)
This section provides a real-time view of insider transactions for Denali Therapeutics Inc. (DNLI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Denali Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Denali Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 11
2021
|
Carole Ho Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
3,156
-0.9%
|
$220,920
$70.83 P/Share
|
|
Feb 09
2021
|
Carole Ho Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
1,470
-0.29%
|
$110,250
$75.17 P/Share
|
|
Feb 09
2021
|
Steve E. Krognes Director |
SELL
Open market or private sale
|
Direct |
1,448
-5.13%
|
$107,152
$74.88 P/Share
|
|
Feb 09
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
1,468
-0.14%
|
$110,100
$75.17 P/Share
|
|
Feb 09
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
5,112
-0.07%
|
$378,288
$74.12 P/Share
|
|
Feb 08
2021
|
Ryan J. Watts President and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,316
+0.31%
|
-
|
|
Feb 07
2021
|
Carole Ho Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,250
+2.45%
|
-
|
|
Feb 07
2021
|
Steve E. Krognes Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,250
+22.76%
|
-
|
|
Feb 07
2021
|
Alexander O. Schuth COFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,250
+0.78%
|
-
|
|
Feb 04
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
10,000
-0.62%
|
$670,000
$67.72 P/Share
|
|
Feb 01
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
18,334
-0.26%
|
$1,265,046
$69.02 P/Share
|
|
Jan 15
2021
|
Steve E. Krognes Director |
SELL
Open market or private sale
|
Indirect |
50,000
-1.27%
|
$3,550,000
$71.51 P/Share
|
|
Jan 04
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
88,334
-0.21%
|
$6,625,050
$75.39 P/Share
|
|
Jan 04
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
70,000
-0.67%
|
$5,180,000
$74.87 P/Share
|
|
Dec 21
2020
|
David P Schenkein Director |
SELL
Open market or private sale
|
Indirect |
5,000
-16.01%
|
$450,000
$90.01 P/Share
|
|
Dec 21
2020
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
25,000
-100.0%
|
$2,250,000
$90.06 P/Share
|
|
Dec 21
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
383,411
-100.0%
|
-
|
|
Dec 14
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
17,825
-2.23%
|
$1,426,000
$80.74 P/Share
|
|
Dec 11
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
46,799
-10.45%
|
$3,743,920
$80.05 P/Share
|
|
Nov 12
2020
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
30,000
-54.55%
|
$2,100,000
$70.05 P/Share
|
|
Nov 10
2020
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
10,000
-15.38%
|
$600,000
$60.03 P/Share
|
|
Nov 04
2020
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
10,000
-13.33%
|
$500,000
$50.18 P/Share
|
|
Oct 09
2020
|
Carole Ho Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
30,000
-7.91%
|
$1,230,000
$41.09 P/Share
|
|
Oct 09
2020
|
Carole Ho Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
30,000
+13.24%
|
$150,000
$5.28 P/Share
|
|
Oct 08
2020
|
Carole Ho Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
22,906
-12.09%
|
$916,240
$40.12 P/Share
|
|
Oct 08
2020
|
Carole Ho Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
22,906
+10.78%
|
$114,530
$5.28 P/Share
|
|
Aug 12
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,443,247
-10.58%
|
$44,740,657
$31.65 P/Share
|
|
Jun 30
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
45,345
-4.6%
|
$1,088,280
$24.18 P/Share
|
|
Jun 29
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
82,578
-7.39%
|
$1,981,872
$24.17 P/Share
|
|
Jun 26
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
122,077
-8.92%
|
$2,929,848
$24.26 P/Share
|
|
Jun 23
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,024
-1.4%
|
$500,600
$25.94 P/Share
|
|
Jun 22
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
90,056
-5.71%
|
$2,161,344
$24.89 P/Share
|
|
Jun 19
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
144,920
-7.91%
|
$3,478,080
$24.6 P/Share
|
|
Jun 05
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,922,855
-12.35%
|
$48,071,375
$25.75 P/Share
|
|
Feb 26
2020
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,894,764
-20.01%
|
$77,895,280
$20.25 P/Share
|
|
Mar 25
2019
|
Douglas K Bratton > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
158,764
-14.28%
|
-
|
|
Dec 12
2017
|
Fil LTD |
BUY
Conversion of derivative security
|
Indirect |
1,775,856
+16.21%
|
-
|
|
Dec 12
2017
|
Fil LTD |
BUY
Conversion of derivative security
|
Direct |
1,497,951
+16.22%
|
-
|
|
Dec 12
2017
|
Douglas K Bratton > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
275,000
+1.39%
|
$4,950,000
$18.0 P/Share
|
|
Dec 12
2017
|
Douglas K Bratton > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
19,986,798
+25.26%
|
-
|
|
Dec 12
2017
|
Flagship Ventures Fund V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
8,606,249
+49.11%
|
-
|